Companies: 10,795·Total market cap: $144.5T
CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSPNASDAQHealthcare● Active
$4.86
$-0.14(-2.80%)
Market Cap$2792516
P/E Ratio—
52W High$12.84
52W Low$1.9
ForecastMarket CapPE Ratio

CNS Pharmaceuticals, Inc.（CNSP）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

cnsp · 股价预测 · 4 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 4 位华尔街分析师

SellBuy

Buy

4 位分析师

共识

评级分布

Strong Buy
0
Buy
4
Hold
0
Sell
0
Strong Sell
0
合计: 4 · 买入占比: 100.0%

12 个月目标价

High

$0.50

Consensus

$0.50

-89.8% upside

Low

$0.50

Median: $0.5 · Last Close: $4.92

CNS Pharmaceuticals, Inc.（CNSP）的分析师共识为 Buy，基于过去 3 个月内 4 位华尔街分析师的评级。CNSP 的 12 个月平均目标价为 $0.50，相对当前价 $4.92 代表 -89.8% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

Low Activity

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-09$4.84↓ 1.78%

1-day model range: $4.71–$4.97. Peak: $4.97 (-1.78%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)53.4
MACDNEUTRAL

Moving Averages · CNSP · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$5.07SELL
MA 10$5.11SELL
MA 20$5.22SELL
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $CNSP · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$5.05SELL
EMA 10$5.15SELL
EMA 20$5.49SELL
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $CNSP · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Maxim Group2025-09-12
Upgrade ↑
Hold→Buy
Maxim Group2025-03-25
Downgrade ↓
Buy→Hold
Brookline Capital2021-02-02
Maintains
Buy→Buy
Ladenburg Thalmann2020-08-24
Maintains
Buy→Buy
Benchmark2019-12-04
Maintains
Speculative Buy→Buy

Wall Street analysts have recently issued updated ratings on CNS Pharmaceuticals, Inc. (CNSP) stock. Of the recent 5 rating actions, 1 were upgrades and 1 were downgrades. 4 analysts currently cover CNSP.

分析师推荐趋势

Buy ratings1 → 1
Hold ratings0 → 0
Sell ratings0 → 0

CNSP analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$41M

↓ 46.5% YoY

Revenue Next Year

$50M

↑ 22.7% YoY

EPS This Year

$-1.65

EPS Next Year

$-1.66

↑ 0.6% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CNSP EPS of $-1.65 for the current fiscal year, based on estimates from 1 analysts. The CNSP revenue forecast is $41M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

CNSP 股价预测由两类独立数据源支撑：来自 4 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CNSP 的共识目标价为 $0.50（-89.8% 上行空间），分析师共识为 Buy。

CNSP 的短期预测（明日）为 $4.84（-1.78%）。

CNS Pharmaceuticals, Inc. 在 NASDAQ 上市，代码 CNSP。CNSP 在 2027 年的整体展望偏积极，在覆盖分析师中约 100% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

CNSP 预测 · 8 个问题

根据 4 位华尔街分析师，CNSP 的 12 个月平均目标价为 $0.50，最高 $0.50、最低 $0.50。若有图表，中位目标价可在上方查看。相对当前价 $4.92，隐含约 -89.8% 的上行空间。

CNSP 目标价CNSP 分析师目标价CNSP 12个月目标价目标价 CNSP

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.